5.2M XNAS Volume
XNAS 17 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 68,243 | 136,487 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 25,667 | 281,391 (0%) | 0% | - | Common Stock | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 32,904 | 314,295 (0%) | 0% | - | Common Stock | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 68,243 | 382,538 (0%) | 0% | - | Common Stock | |
| Alan J. Main | EVP, Innov & Chem Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 28 Feb 2025 | 43,434 | 339,104 (0%) | 0% | 0.7 | 29,101 | Common Stock |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 25,667 | 0 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 32,904 | 32,903 | - | - | Restricted Stock Units | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 69,387 | 306,437 (0%) | 0% | - | Common Stock | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 69,387 | 138,773 | - | - | Restricted Stock Units | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 33,456 | 33,457 | - | - | Restricted Stock Units | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 26,097 | 0 | - | - | Restricted Stock Units | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 26,097 | 203,594 (0%) | 0% | - | Common Stock | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 33,456 | 237,050 (0%) | 0% | - | Common Stock | |
| Brian T. Crum | SVP, General Counsel & Secr. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 28 Feb 2025 | 45,622 | 260,815 (0%) | 0% | 0.7 | 30,567 | Common Stock |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 19,887 | 39,773 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 10,617 | 58,417 (0%) | 0% | - | Common Stock | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 15,926 | 74,343 (0%) | 0% | - | Common Stock | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 19,887 | 94,230 (0%) | 0% | - | Common Stock | |
| Kristen L. Alexander | VP, Finance and Accounting | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 28 Feb 2025 | 17,862 | 76,368 (0%) | 0% | 0.7 | 11,968 | Common Stock |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 10,617 | 0 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 15,926 | 15,927 | - | - | Restricted Stock Units | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 74,227 | 148,453 | - | - | Restricted Stock Units | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 27,917 | 75,543 (0%) | 0% | - | Common Stock | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 35,790 | 111,333 (0%) | 0% | - | Common Stock | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 74,227 | 185,560 (0%) | 0% | - | Common Stock | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 28 Feb 2025 | 65,308 | 120,252 (0%) | 0% | 0.7 | 43,756 | Common Stock |
| Craig B. Granowitz | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 27,917 | 0 | - | - | Restricted Stock Units | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 35,790 | 35,790 | - | - | Restricted Stock Units | |
| Wendy E. McDermott | SVP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 28 Feb 2025 | 30,004 | 121,646 (0%) | 0% | 0.7 | 20,103 | Common Stock |
| Wendy E. McDermott | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 18,943 | 0 | - | - | Restricted Stock Units | |
| Wendy E. McDermott | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 27,696 | 27,697 | - | - | Restricted Stock Units | |
| Wendy E. McDermott | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 52,317 | 104,633 | - | - | Restricted Stock Units | |
| Wendy E. McDermott | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 18,943 | 71,637 (0%) | 0% | - | Common Stock | |
| Wendy E. McDermott | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 27,696 | 99,333 (0%) | 0% | - | Common Stock | |
| Wendy E. McDermott | SVP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 52,317 | 151,650 (0%) | 0% | - | Common Stock | |
| Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 502,060 | 502,060 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 753,090 | 753,090 | - | - | Stock Option (Right to Buy) | |
| Brian T. Crum | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 765,730 | 765,730 | - | - | Stock Option (Right to Buy) | |
| Brian T. Crum | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 510,490 | 510,490 | - | - | Restricted Stock Units | |
| Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 480,710 | 480,710 | - | - | Restricted Stock Units | |
| Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 721,070 | 721,070 | - | - | Stock Option (Right to Buy) | |
| Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 185,540 | 185,540 | - | - | Stock Option (Right to Buy) | |
| Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 185,540 | 185,540 | - | - | Restricted Stock Units | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 606,780 | 606,780 | - | - | Restricted Stock Units | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 910,170 | 910,170 | - | - | Stock Option (Right to Buy) | |
| Wendy E. McDermott | SVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 649,780 | 649,780 | - | - | Stock Option (Right to Buy) | |
| Wendy E. McDermott | SVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 433,180 | 433,180 | - | - | Restricted Stock Units | |
| Michael Exton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 1,509,790 | 1,509,790 | - | - | Restricted Stock Units | |
| Michael Exton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 2,264,690 | 2,264,690 | - | - | Stock Option (Right to Buy) | |
| Brian Corrigan | SVP, Regulatory & QA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 448,660 | 448,660 | - | - | Restricted Stock Units | |
| Brian Corrigan | SVP, Regulatory & QA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 673,000 | 673,000 | - | - | Stock Option (Right to Buy) | |
| Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 230,000 | 230,000 | - | - | Stock Option (Right to Buy) | |
| Ivan H. Cheung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2024 | 186,685 | 186,685 | - | - | Stock Option (Right to Buy) | |
| Brian Corrigan | SVP, Regulatory & QA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey L. Wade | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2024 | 307,000 | 307,000 | - | - | Stock Option (Right to Buy) | |
| Michael Exton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2024 | 1,675,000 | 1,675,000 | - | - | Stock Option (Right to Buy) | |
| Raymond Debbane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 44,906 | 44,906 | - | - | Stock Option (Right to Buy) | |
| Raymond Debbane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 36,810 | 36,810 | - | - | Restricted Stock Units | |
| Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 44,906 | 44,906 | - | - | Stock Option (Right to Buy) | |
| Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 36,810 | 36,810 | - | - | Restricted Stock Units | |
| Christopher J. Sobecki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 44,906 | 44,906 | - | - | Stock Option (Right to Buy) | |
| Christopher J. Sobecki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 36,810 | 36,810 | - | - | Restricted Stock Units | |
| Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 44,906 | 44,906 | - | - | Stock Option (Right to Buy) | |
| Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 36,810 | 36,810 | - | - | Restricted Stock Units | |
| Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 44,906 | 44,906 | - | - | Stock Option (Right to Buy) | |
| Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 36,810 | 36,810 | - | - | Restricted Stock Units | |
| Robert J. Lefkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 44,906 | 44,906 | - | - | Stock Option (Right to Buy) | |
| Robert J. Lefkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 36,810 | 36,810 | - | - | Restricted Stock Units | |
| Diane E. Sullivan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 36,810 | 36,810 | - | - | Restricted Stock Units | |
| Diane E. Sullivan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 44,906 | 44,906 | - | - | Stock Option (Right to Buy) | |
| Raymond Debbane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 1,348,879 (1%) | 0% | 0 | Common Stock | |
| Raymond Debbane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 0 | - | - | Restricted Stock Units | |
| Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 0 | - | - | Restricted Stock Units | |
| Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 87,649 (0%) | 0% | 0 | Common Stock | |
| Christopher J. Sobecki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 167,055 (0%) | 0% | 0 | Common Stock | |
| Christopher J. Sobecki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 0 | - | - | Restricted Stock Units | |
| Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 0 | - | - | Restricted Stock Units | |
| Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 248,364 (0%) | 0% | 0 | Common Stock | |
| Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 48,364 (0%) | 0% | 0 | Common Stock | |
| Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 0 | - | - | Restricted Stock Units | |
| Robert J. Lefkowitz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 0 | - | - | Restricted Stock Units | |
| Robert J. Lefkowitz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 48,364 (0%) | 0% | 0 | Common Stock | |
| B. Kassler-Taub Kenneth | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 27,556 | 154,268 (0%) | 0% | - | Common Stock | |
| Crum T. Brian | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 8,750 | 0 | - | - | Restricted Stock Units | |
| T. Crum Brian | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 33,457 | 203,101 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 33,333 | 0 | - | - | Restricted Stock Units | |
| T. Brian Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 26,096 | 26,097 | - | - | Restricted Stock Units | |
| B. Kassler-Taub Kenneth | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 7,087 | 126,712 (0%) | 0% | - | Common Stock | |
| Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 37,274 | 312,792 (0%) | 0% | - | Common Stock | |
| Kassler-Taub Kenneth B. | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 32,757 | 187,025 (0%) | 0% | - | Common Stock | |
| Crum T. Brian | SVP, General Counsel & Secr. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.62 per share. | 28 Feb 2024 | 25,604 | 177,497 (0%) | 0% | 2.6 | 67,082 | Common Stock |
| Alexander L. Kristen | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 15,927 | 59,593 (0%) | 0% | - | Common Stock | |
| McDermott Wendy E. | VP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 18,944 | 18,943 | - | - | Restricted Stock Units | |
| Craig Granowitz B. | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 27,916 | 43,101 (0%) | 0% | - | Common Stock | |
| Kassler-Taub Kenneth B. | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 7,087 | 0 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 32,903 | 280,132 (0%) | 0% | - | Common Stock | |
| Alexander L. Kristen | VP, Finance and Accounting | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.62 per share. | 28 Feb 2024 | 11,793 | 47,800 (0%) | 0% | 2.6 | 30,898 | Common Stock |
| McDermott E. Wendy | VP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.62 per share. | 28 Feb 2024 | 22,425 | 52,694 (0%) | 0% | 2.6 | 58,754 | Common Stock |
| Coats Lonnel | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.62 per share. | 28 Feb 2024 | 61,371 | 1,098,068 (1%) | 0% | 2.6 | 160,792 | Common Stock |
| Wade Jeffrey L. | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.62 per share. | 28 Feb 2024 | 37,691 | 324,214 (0%) | 0% | 2.6 | 98,750 | Common Stock |
| Granowitz Craig B. | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 35,790 | 78,891 (0%) | 0% | - | Common Stock | |
| Jeffrey Wade L. | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 11,177 | 275,518 (0%) | 0% | - | Common Stock | |
| Kassler-Taub Kenneth B. | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 32,757 | 65,513 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 10,616 | 10,617 | - | - | Restricted Stock Units | |
| Coats Lonnel | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 120,383 | 240,767 | - | - | Restricted Stock Units | |
| Wade Jeffrey L. | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 37,274 | 37,273 | - | - | Restricted Stock Units | |
| B. Craig Granowitz | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 27,916 | 27,917 | - | - | Restricted Stock Units | |
| B. Kenneth Kassler-Taub | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 27,556 | 27,557 | - | - | Restricted Stock Units | |
| McDermott Wendy E. | VP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 27,697 | 55,393 | - | - | Restricted Stock Units | |
| Coats Lonnel | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 33,333 | 947,692 (0%) | 0% | - | Common Stock | |
| J. Main Alan | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 25,666 | 25,667 | - | - | Restricted Stock Units | |
| McDermott Wendy E. | VP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 27,697 | 75,119 (0%) | 0% | - | Common Stock | |
| Crum T. Brian | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 33,457 | 66,913 | - | - | Restricted Stock Units | |
| Alan Main J. | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 8,977 | 0 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 32,903 | 65,807 | - | - | Restricted Stock Units | |
| Crum Brian T. | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 26,096 | 169,644 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 91,364 | 91,363 | - | - | Restricted Stock Units | |
| Kristen Alexander L. | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 2,700 | 0 | - | - | Restricted Stock Units | |
| J. Alan Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 25,666 | 247,229 (0%) | 0% | - | Common Stock | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 10,616 | 43,666 (0%) | 0% | - | Common Stock | |
| L. Jeffrey Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 11,177 | 0 | - | - | Restricted Stock Units | |
| Kristen Alexander L. | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 2,700 | 33,050 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 91,364 | 1,039,056 (0%) | 0% | - | Common Stock | |
| Alexander Kristen L. | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 15,927 | 31,853 | - | - | Restricted Stock Units | |
| Main J. Alan | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 8,977 | 221,563 (0%) | 0% | - | Common Stock | |
| Jeffrey Wade L. | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 49,113 | 361,905 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 120,383 | 1,159,439 (1%) | 0% | - | Common Stock | |
| Alan J. Main | EVP, Innov & Chem Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.62 per share. | 28 Feb 2024 | 24,408 | 255,724 (0%) | 0% | 2.6 | 63,949 | Common Stock |
| Granowitz B. Craig | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 35,790 | 71,580 | - | - | Restricted Stock Units | |
| B. Kassler-Taub Kenneth | SVP, Regulatory & QA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.62 per share. | 28 Feb 2024 | 24,353 | 162,672 (0%) | 0% | 2.6 | 63,805 | Common Stock |
| McDermott Wendy E. | VP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 18,944 | 47,422 (0%) | 0% | - | Common Stock | |
| Wade Jeffrey L. | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 49,113 | 98,227 | - | - | Restricted Stock Units | |
| B. Granowitz Craig | SVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.62 per share. | 28 Feb 2024 | 31,265 | 47,626 (0%) | 0% | 2.6 | 81,914 | Common Stock |
| Crum T. Brian | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 8,750 | 143,548 (0%) | 0% | - | Common Stock | |
| E. McDermott Wendy | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 156,950 | 156,950 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 59,660 | 59,660 | - | - | Stock Option (Right to Buy) | |
| Granowitz B. Craig | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 222,680 | 222,680 | - | - | Restricted Stock Units | |
| Lonnel Coats | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 770,420 | 770,420 | - | - | Restricted Stock Units | |
| B. Kenneth Kassler-Taub | SVP, Regulatory & QA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 203,810 | 203,810 | - | - | Stock Option (Right to Buy) | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 203,810 | 203,810 | - | - | Restricted Stock Units | |
| Crum Brian T. | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 208,160 | 208,160 | - | - | Stock Option (Right to Buy) | |
| Lonnel Coats | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 770,420 | 770,420 | - | - | Stock Option (Right to Buy) | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 222,680 | 222,680 | - | - | Stock Option (Right to Buy) | |
| E. Wendy McDermott | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 156,950 | 156,950 | - | - | Stock Option (Right to Buy) | |
| L. Wade Jeffrey | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 314,320 | 314,320 | - | - | Restricted Stock Units | |
| Wade L. Jeffrey | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 314,320 | 314,320 | - | - | Stock Option (Right to Buy) | |
| Garner Thomas | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 227,130 | 227,130 | - | - | Restricted Stock Units | |
| Alexander L. Kristen | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 59,660 | 59,660 | - | - | Restricted Stock Units | |
| Main J. Alan | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 204,730 | 204,730 | - | - | Stock Option (Right to Buy) | |
| J. Main Alan | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 204,730 | 204,730 | - | - | Restricted Stock Units | |
| T. Crum Brian | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 208,160 | 208,160 | - | - | Restricted Stock Units | |
| Garner Thomas | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 227,130 | 227,130 | - | - | Stock Option (Right to Buy) | |
| Wendy E. McDermott | VP, Human Resources | Purchase of securities on an exchange or from another person at price $ 1.84 per share. | 04 Aug 2023 | 6,000 | 28,478 (0%) | 0% | 1.8 | 11,040 | Common Stock |
| Diane Sullivan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2023 | 96,515 | 96,515 | - | - | Stock Option (Right to Buy) | |
| Lonnel Coats | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.16 per share. | 29 Jun 2023 | 10,000 | 814,359 (0%) | 0% | 2.2 | 21,600 | Common Stock |
| Lonnel Coats | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.50 per share. | 23 Jun 2023 | 10,000 | 794,359 (0%) | 0% | 2.5 | 24,950 | Common Stock |
| Lonnel Coats | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.18 per share. | 23 Jun 2023 | 10,000 | 804,359 (0%) | 0% | 2.2 | 21,792 | Common Stock |
| Wendy E. McDermott | VP, Human Resources | Purchase of securities on an exchange or from another person at price $ 2.43 per share. | 23 Jun 2023 | 10,000 | 22,478 (0%) | 0% | 2.4 | 24,300 | Common Stock |
| Lonnel Coats | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.31 per share. | 22 Jun 2023 | 40,000 | 784,359 (0%) | 0% | 2.3 | 92,400 | Common Stock |
| Jeffrey L. Wade | President and CFO | Purchase of securities on an exchange or from another person at price $ 2.32 per share. | 20 Jun 2023 | 2,000 | 254,341 (0%) | 0% | 2.3 | 4,650 | Common Stock |
| Jeffrey L. Wade | President and CFO | Purchase of securities on an exchange or from another person at price $ 2.34 per share. | 20 Jun 2023 | 10,000 | 252,341 (0%) | 0% | 2.3 | 23,350 | Common Stock |
| Frank P. Palantoni | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 40,332 (0%) | 0% | 0 | Common Stock | |
| Frank P. Palantoni | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 0 | - | - | Restricted Stock Units | |
| Raymond Debbane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 0 | - | - | Restricted Stock Units | |
| Raymond Debbane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 340,847 (0%) | 0% | 0 | Common Stock | |
| Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 79,617 (0%) | 0% | 0 | Common Stock | |
| Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 0 | - | - | Restricted Stock Units | |
| Alan S. Nies | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 41,046 (0%) | 0% | 0 | Common Stock | |
| Alan S. Nies | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 0 | - | - | Restricted Stock Units | |
| Christopher J. Sobecki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 159,023 (0%) | 0% | 0 | Common Stock | |
| Christopher J. Sobecki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 0 | - | - | Restricted Stock Units | |
| Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 0 | - | - | Restricted Stock Units | |
| Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 40,332 (0%) | 0% | 0 | Common Stock | |
| Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 0 | - | - | Restricted Stock Units | |
| Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 40,332 (0%) | 0% | 0 | Common Stock | |
| Robert J. Lefkowitz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 0 | - | - | Restricted Stock Units | |
| Robert J. Lefkowitz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 40,332 (0%) | 0% | 0 | Common Stock | |
| Frank P. Palantoni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 12,658 | 12,658 | - | - | Stock Option (Right to Buy) | |
| Frank P. Palantoni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 8,032 | 8,032 | - | - | Restricted Stock Units | |
| Alan S. Nies | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 8,032 | 8,032 | - | - | Restricted Stock Units | |
| Alan S. Nies | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 12,658 | 12,658 | - | - | Stock Option (Right to Buy) | |
| Christopher J. Sobecki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 8,032 | 8,032 | - | - | Restricted Stock Units | |
| Christopher J. Sobecki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 12,658 | 12,658 | - | - | Stock Option (Right to Buy) | |
| Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 12,658 | 12,658 | - | - | Stock Option (Right to Buy) | |
| Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 8,032 | 8,032 | - | - | Restricted Stock Units | |
| Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 8,032 | 8,032 | - | - | Restricted Stock Units | |
| Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 12,658 | 12,658 | - | - | Stock Option (Right to Buy) | |
| Robert J. Lefkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 8,032 | 8,032 | - | - | Restricted Stock Units | |
| Robert J. Lefkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 12,658 | 12,658 | - | - | Stock Option (Right to Buy) | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 23,300 | 0 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 20,946 | 212,586 (0%) | 0% | 2.2 | 45,453 | Common Stock |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 8,976 | 8,977 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 25,667 | 233,532 (0%) | 0% | - | Common Stock | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 8,976 | 207,865 (0%) | 0% | - | Common Stock | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 25,667 | 51,333 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 23,300 | 198,889 (0%) | 0% | - | Common Stock | |
| Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 37,273 | 74,547 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 11,176 | 11,177 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 30,467 | 0 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 30,255 | 242,341 (0%) | 0% | 2.2 | 65,653 | Common Stock |
| Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 37,273 | 272,596 (0%) | 0% | - | Common Stock | |
| Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 11,176 | 235,323 (0%) | 0% | - | Common Stock | |
| Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 30,467 | 224,147 (0%) | 0% | - | Common Stock | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 26,097 | 52,193 | - | - | Restricted Stock Units | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 8,750 | 8,750 | - | - | Restricted Stock Units | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 21,030 | 0 | - | - | Restricted Stock Units | |
| Brian T. Crum | SVP, General Counsel & Secr. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 20,537 | 134,798 (0%) | 0% | 2.2 | 44,565 | Common Stock |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 26,097 | 155,335 (0%) | 0% | - | Common Stock | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 8,750 | 129,238 (0%) | 0% | - | Common Stock | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 21,030 | 120,488 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 84,630 | 0 | - | - | Restricted Stock Units | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 84,630 | 670,633 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 33,334 | 703,967 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 91,363 | 795,330 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 50,971 | 744,359 (0%) | 0% | 2.2 | 110,607 | Common Stock |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 33,334 | 33,333 | - | - | Restricted Stock Units | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 91,363 | 182,727 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 10,617 | 21,233 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 2,700 | 2,700 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 5,400 | 0 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 5,330 | 30,350 (0%) | 0% | 2.2 | 11,566 | Common Stock |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 10,617 | 35,680 (0%) | 0% | - | Common Stock | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 2,700 | 25,063 (0%) | 0% | - | Common Stock | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 5,400 | 22,363 (0%) | 0% | - | Common Stock | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 12,732 | 15,185 (0%) | 0% | 2.2 | 27,628 | Common Stock |
| Craig B. Granowitz | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 27,917 | 27,917 (0%) | 0% | - | Common Stock | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 27,917 | 55,833 | - | - | Restricted Stock Units | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 18,243 | 104,100 (0%) | 0% | - | Common Stock | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 27,557 | 55,113 | - | - | Restricted Stock Units | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 7,086 | 7,087 | - | - | Restricted Stock Units | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 18,243 | 0 | - | - | Restricted Stock Units | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 19,118 | 119,625 (0%) | 0% | 2.2 | 41,486 | Common Stock |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 27,557 | 138,743 (0%) | 0% | - | Common Stock | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 7,086 | 111,186 (0%) | 0% | - | Common Stock | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 22,963 | 45,927 | - | - | Restricted Stock Units | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 11,813 | 53,136 (0%) | 0% | 2.2 | 25,634 | Common Stock |
| Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 14,833 | 0 | - | - | Restricted Stock Units | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 5,286 | 5,287 | - | - | Restricted Stock Units | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 14,833 | 36,700 (0%) | 0% | - | Common Stock | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 5,286 | 41,986 (0%) | 0% | - | Common Stock | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 22,963 | 64,949 (0%) | 0% | - | Common Stock | |
| Wendy E. McDermott | VP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 18,943 | 18,943 (0%) | 0% | - | Common Stock | |
| Wendy E. McDermott | VP, Human Resources | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 18,943 | 37,887 | - | - | Restricted Stock Units | |
| Wendy E. McDermott | VP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 6,465 | 12,478 (0%) | 0% | 2.2 | 14,029 | Common Stock |
| Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 296,130 | 296,130 | - | - | Stock Option (Right to Buy) | |
| Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 98,710 | 98,710 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 147,340 | 147,340 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 442,030 | 442,030 | - | - | Stock Option (Right to Buy) | |
| Brian T. Crum | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 100,370 | 100,370 | - | - | Restricted Stock Units | |
| Brian T. Crum | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 301,100 | 301,100 | - | - | Stock Option (Right to Buy) | |
| Lonnel Coats | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 1,083,440 | 1,083,440 | - | - | Stock Option (Right to Buy) | |
| Lonnel Coats | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 361,150 | 361,150 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 71,670 | 71,670 | - | - | Stock Option (Right to Buy) | |
| Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 47,780 | 47,780 | - | - | Restricted Stock Units | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 322,110 | 322,110 | - | - | Stock Option (Right to Buy) | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 107,370 | 107,370 | - | - | Restricted Stock Units | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 98,270 | 98,270 | - | - | Restricted Stock Units | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 294,810 | 294,810 | - | - | Stock Option (Right to Buy) | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 280,100 | 280,100 | - | - | Stock Option (Right to Buy) | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 93,370 | 93,370 | - | - | Restricted Stock Units | |
| Wendy E. McDermott | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 83,090 | 83,090 | - | - | Restricted Stock Units | |
| Wendy E. McDermott | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 249,280 | 249,280 | - | - | Stock Option (Right to Buy) | |
| Raymond Debbane | Director | Purchase of securities on an exchange or from another person at price $ 2.50 per share. | 01 Aug 2022 | 982,600 | 5,303,814 (4%) | 0% | 2.5 | 2,456,500 | Common Stock |
| Frank P. Palantoni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 14,402 | 14,402 | - | - | Stock Option (Right to Buy) | |
| Frank P. Palantoni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 9,302 | 9,302 | - | - | Restricted Stock Units | |
| Raymond Debbane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 9,302 | 9,302 | - | - | Restricted Stock Units | |
| Raymond Debbane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 14,402 | 14,402 | - | - | Stock Option (Right to Buy) | |
| Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 14,402 | 14,402 | - | - | Stock Option (Right to Buy) | |
| Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 9,302 | 9,302 | - | - | Restricted Stock Units | |
| Alan S. Nies | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 9,302 | 9,302 | - | - | Restricted Stock Units | |
| Alan S. Nies | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 14,402 | 14,402 | - | - | Stock Option (Right to Buy) | |
| Christopher J. Sobecki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 14,402 | 14,402 | - | - | Stock Option (Right to Buy) | |
| Christopher J. Sobecki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 9,302 | 9,302 | - | - | Restricted Stock Units | |
| Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 9,302 | 9,302 | - | - | Restricted Stock Units | |
| Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 14,402 | 14,402 | - | - | Stock Option (Right to Buy) | |
| Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 14,402 | 14,402 | - | - | Stock Option (Right to Buy) | |
| Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 9,302 | 9,302 | - | - | Restricted Stock Units | |
| Robert J. Lefkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 9,302 | 9,302 | - | - | Restricted Stock Units | |
| Robert J. Lefkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 14,402 | 14,402 | - | - | Stock Option (Right to Buy) | |
| Frank P. Palantoni | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 0 | - | - | Restricted Stock Units | |
| Frank P. Palantoni | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 31,030 (0%) | 0% | 0 | Common Stock | |
| Raymond Debbane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 331,545 (0%) | 0% | 0 | Common Stock | |
| Raymond Debbane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 0 | - | - | Restricted Stock Units | |
| Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 70,315 (0%) | 0% | 0 | Common Stock | |
| Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 0 | - | - | Restricted Stock Units | |
| Alan S. Nies | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 31,744 (0%) | 0% | 0 | Common Stock | |
| Alan S. Nies | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 0 | - | - | Restricted Stock Units | |
| Christopher J. Sobecki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 149,721 (0%) | 0% | 0 | Common Stock | |
| Christopher J. Sobecki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 0 | - | - | Restricted Stock Units | |
| Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 0 | - | - | Restricted Stock Units | |
| Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 31,030 (0%) | 0% | 0 | Common Stock | |
| Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 31,030 (0%) | 0% | 0 | Common Stock | |
| Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 0 | - | - | Restricted Stock Units | |
| Robert J. Lefkowitz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 31,030 (0%) | 0% | 0 | Common Stock | |
| Robert J. Lefkowitz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 0 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 22,373 | 163,068 (0%) | 0% | - | Common Stock | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 8,977 | 17,953 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 22,373 | 0 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 23,300 | 23,300 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.85 per share. | 28 Feb 2022 | 19,756 | 175,589 (0%) | 0% | 2.9 | 56,305 | Common Stock |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 8,977 | 195,345 (0%) | 0% | - | Common Stock | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 23,300 | 186,368 (0%) | 0% | - | Common Stock | |
| Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 30,466 | 30,467 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 11,177 | 22,353 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.85 per share. | 28 Feb 2022 | 25,773 | 193,680 (0%) | 0% | 2.8 | 73,453 | Common Stock |
| Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 11,177 | 219,453 (0%) | 0% | - | Common Stock | |
| Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 30,466 | 208,276 (0%) | 0% | - | Common Stock | |
| Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 25,290 | 177,810 (0%) | 0% | - | Common Stock | |
| Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 25,290 | 0 | - | - | Restricted Stock Units | |
| Brian T. Crum | SVP, General Counsel & Secr. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.85 per share. | 28 Feb 2022 | 15,059 | 99,458 (0%) | 0% | 2.8 | 42,918 | Common Stock |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 8,750 | 114,517 (0%) | 0% | - | Common Stock | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 21,030 | 105,767 (0%) | 0% | - | Common Stock | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 11,100 | 84,737 (0%) | 0% | - | Common Stock | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 21,030 | 21,030 | - | - | Restricted Stock Units | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 8,750 | 17,500 | - | - | Restricted Stock Units | |
| Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 11,100 | 0 | - | - | Restricted Stock Units | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 79,380 | 0 | - | - | Restricted Stock Units | |
| Lonnel Coats | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.85 per share. | 28 Feb 2022 | 48,053 | 586,003 (0%) | 0% | 2.8 | 136,951 | Common Stock |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 33,333 | 634,056 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 84,630 | 600,723 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 79,380 | 516,093 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 33,333 | 66,667 | - | - | Restricted Stock Units | |
| Lonnel Coats | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 84,630 | 84,630 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,700 | 20,300 (0%) | 0% | - | Common Stock | |
| Kristen L. Alexander | VP, Finance and Accounting | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.85 per share. | 28 Feb 2022 | 3,337 | 16,963 (0%) | 0% | 2.8 | 9,510 | Common Stock |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 3,200 | 0 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 5,400 | 5,400 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,700 | 5,400 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 3,200 | 12,200 (0%) | 0% | - | Common Stock | |
| Kristen L. Alexander | VP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 5,400 | 17,600 (0%) | 0% | - | Common Stock | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 11,297 | 0 | - | - | Restricted Stock Units | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 11,297 | 73,767 (0%) | 0% | - | Common Stock | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 18,244 | 92,011 (0%) | 0% | - | Common Stock | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 7,087 | 99,098 (0%) | 0% | - | Common Stock | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.85 per share. | 28 Feb 2022 | 13,241 | 85,857 (0%) | 0% | 2.9 | 37,737 | Common Stock |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 18,244 | 18,243 | - | - | Restricted Stock Units | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 7,087 | 14,173 | - | - | Restricted Stock Units | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 5,287 | 10,573 | - | - | Restricted Stock Units | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.85 per share. | 28 Feb 2022 | 8,261 | 21,867 (0%) | 0% | 2.9 | 23,544 | Common Stock |
| Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 5,287 | 30,128 (0%) | 0% | - | Common Stock | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 14,834 | 24,841 (0%) | 0% | - | Common Stock | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 10,007 | 10,007 (0%) | 0% | - | Common Stock | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 14,834 | 14,833 | - | - | Restricted Stock Units | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 10,007 | 0 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 230,990 | 230,990 | - | - | Stock Option (Right to Buy) | |
| Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 77,000 | 77,000 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 111,820 | 111,820 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 335,470 | 335,470 | - | - | Stock Option (Right to Buy) | |
| Brian T. Crum | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 234,870 | 234,870 | - | - | Stock Option (Right to Buy) | |
| Brian T. Crum | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 78,290 | 78,290 | - | - | Restricted Stock Units | |
| Lonnel Coats | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 822,280 | 822,280 | - | - | Stock Option (Right to Buy) | |
| Lonnel Coats | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 274,090 | 274,090 | - | - | Restricted Stock Units | |
| Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 47,780 | 47,780 | - | - | Stock Option (Right to Buy) | |
| Kristen L. Alexander | VP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 31,850 | 31,850 | - | - | Restricted Stock Units | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 83,750 | 83,750 | - | - | Restricted Stock Units | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 251,250 | 251,250 | - | - | Stock Option (Right to Buy) | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 82,670 | 82,670 | - | - | Restricted Stock Units | |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 248,010 | 248,010 | - | - | Stock Option (Right to Buy) | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 206,670 | 206,670 | - | - | Stock Option (Right to Buy) | |
| Kiernan A. Seth | VP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 68,890 | 68,890 | - | - | Restricted Stock Units | |
| Wendy E. McDermott | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 170,500 | 170,500 | - | - | Stock Option (Right to Buy) | |
| Wendy E. McDermott | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 56,830 | 56,830 | - | - | Restricted Stock Units | |
| Wendy E. McDermott | VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 85,185 | 85,185 | - | - | Stock Option (Right to Buy) | |
| Craig B. Granowitz | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Frank P. Palantoni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 4,024 | 4,024 | - | - | Restricted Stock Units | |
| Frank P. Palantoni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 6,475 | 6,475 | - | - | Stock Option (Right to Buy) | |
| Raymond Debbane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 6,475 | 6,475 | - | - | Stock Option (Right to Buy) | |
| Raymond Debbane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 4,024 | 4,024 | - | - | Restricted Stock Units | |
| Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 4,024 | 4,024 | - | - | Restricted Stock Units | |
| Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 6,475 | 6,475 | - | - | Stock Option (Right to Buy) | |
| Alan S. Nies | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 4,024 | 4,024 | - | - | Restricted Stock Units | |
| Alan S. Nies | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 6,475 | 6,475 | - | - | Stock Option (Right to Buy) | |
| Christopher J. Sobecki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 4,024 | 4,024 | - | - | Restricted Stock Units | |
| Christopher J. Sobecki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 6,475 | 6,475 | - | - | Stock Option (Right to Buy) | |
| Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 6,475 | 6,475 | - | - | Stock Option (Right to Buy) | |
| Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 4,024 | 4,024 | - | - | Restricted Stock Units | |
| Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 4,024 | 4,024 | - | - | Restricted Stock Units | |
| Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 6,475 | 6,475 | - | - | Stock Option (Right to Buy) | |
| Robert J. Lefkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 4,024 | 4,024 | - | - | Restricted Stock Units | |
| Robert J. Lefkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 6,475 | 6,475 | - | - | Stock Option (Right to Buy) | |
| Frank P. Palantoni | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 0 | - | - | Restricted Stock Units | |
| Frank P. Palantoni | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 27,006 (0%) | 0% | 0 | Common Stock | |
| Raymond Debbane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 0 | - | - | Restricted Stock Units | |
| Raymond Debbane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 327,521 (0%) | 0% | 0 | Common Stock | |
| Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 0 | - | - | Restricted Stock Units | |
| Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 66,291 (0%) | 0% | 0 | Common Stock | |
| Alan S. Nies | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 27,720 (0%) | 0% | 0 | Common Stock | |
| Alan S. Nies | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 0 | - | - | Restricted Stock Units | |
| Christopher J. Sobecki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 0 | - | - | Restricted Stock Units | |
| Christopher J. Sobecki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 151,397 (0%) | 0% | 0 | Common Stock | |
| Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 0 | - | - | Restricted Stock Units | |
| Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 27,006 (0%) | 0% | 0 | Common Stock | |
| Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 27,006 (0%) | 0% | 0 | Common Stock | |
| Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 0 | - | - | Restricted Stock Units | |
| Robert J. Lefkowitz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 0 | - | - | Restricted Stock Units | |
| Robert J. Lefkowitz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 27,006 (0%) | 0% | 0 | Common Stock | |
| James F. Tessmer | VP, Finance & Accounting | Sale of securities on an exchange or to another person at price $ 6.92 per share. | 15 Mar 2021 | 12,000 | 71,766 (0%) | 0% | 6.9 | 83,100 | Common Stock |
| James F. Tessmer | VP, Finance & Accounting | Sale of securities on an exchange or to another person at price $ 6.90 per share. | 15 Mar 2021 | 10,912 | 71,766 (0%) | 0% | 6.9 | 75,340 | Common Stock |
| James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.31 per share. | 15 Mar 2021 | 12,000 | 83,766 (0%) | 0% | 3.3 | 39,720 | Common Stock |
| James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 12,000 | 50,980 | - | - | Stock Option (Right to Buy) | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 23,300 | 46,600 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,497 | 107,137 (0%) | 0% | - | Common Stock | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 8,297 | 115,434 (0%) | 0% | - | Common Stock | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 22,374 | 137,808 (0%) | 0% | - | Common Stock | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 23,300 | 161,108 (0%) | 0% | - | Common Stock | |
| Alan J. Main | EVP, Innov & Chem Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.19 per share. | 28 Feb 2021 | 20,413 | 140,695 (0%) | 0% | 7.2 | 146,769 | Common Stock |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,497 | 0 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 8,297 | 0 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 22,374 | 22,373 | - | - | Restricted Stock Units | |
| James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,270 | 66,397 (0%) | 0% | - | Common Stock | |
| James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 13,997 | 27,993 | - | - | Restricted Stock Units | |
| James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 8,836 | 8,837 | - | - | Restricted Stock Units | |
| James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,213 | 0 | - | - | Restricted Stock Units | |
| James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,270 | 0 | - | - | Restricted Stock Units | |
| James F. Tessmer | VP, Finance & Accounting | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.19 per share. | 28 Feb 2021 | 10,765 | 82,678 (0%) | 0% | 7.2 | 77,400 | Common Stock |
| James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 13,997 | 93,443 (0%) | 0% | - | Common Stock | |
| James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 8,836 | 79,446 (0%) | 0% | - | Common Stock | |
| James F. Tessmer | VP, Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,213 | 70,610 (0%) | 0% | - | Common Stock | |
| Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,797 | 118,292 (0%) | 0% | - | Common Stock | |
| Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 30,467 | 60,933 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 25,290 | 25,290 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 9,555 | 0 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,797 | 0 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.19 per share. | 28 Feb 2021 | 26,584 | 157,020 (0%) | 0% | 7.2 | 191,139 | Common Stock |
| Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 30,467 | 183,604 (0%) | 0% | - | Common Stock | |
| Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 25,290 | 153,137 (0%) | 0% | - | Common Stock | |
| Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 9,555 | 127,847 (0%) | 0% | - | Common Stock | |
| Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 9,727 | 82,061 (0%) | 0% | - | Common Stock | |
| Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 28,690 | 57,380 | - | - | Restricted Stock Units | |
| Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 26,600 | 26,600 | - | - | Restricted Stock Units | |
| Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 9,727 | 0 | - | - | Restricted Stock Units | |
| Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,990 | 0 | - | - | Restricted Stock Units | |
| Praveen Tyle | EVP, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.19 per share. | 28 Feb 2021 | 16,560 | 120,791 (0%) | 0% | 7.2 | 119,066 | Common Stock |
| Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 28,690 | 137,351 (0%) | 0% | - | Common Stock | |
| Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 26,600 | 108,661 (0%) | 0% | - | Common Stock | |
| Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,990 | 72,334 (0%) | 0% | - | Common Stock | |
| Brian T. Crum | VP, General Counsel & Secr. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.19 per share. | 28 Feb 2021 | 14,860 | 73,637 (0%) | 0% | 7.2 | 106,843 | Common Stock |
| Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 21,030 | 42,060 | - | - | Restricted Stock Units | |
| Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 11,100 | 11,100 | - | - | Restricted Stock Units | |
| Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 5,118 | 0 | - | - | Restricted Stock Units | |
| Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,517 | 0 | - | - | Restricted Stock Units | |
| Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 21,030 | 88,497 (0%) | 0% | - | Common Stock | |
| Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 11,100 | 67,467 (0%) | 0% | - | Common Stock | |
| Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 5,118 | 56,367 (0%) | 0% | - | Common Stock | |
| Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,517 | 51,249 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 5,362 | 304,228 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 23,513 | 327,741 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 79,380 | 407,121 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 84,630 | 491,751 (0%) | 0% | - | Common Stock | |
| Lonnel Coats | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.19 per share. | 28 Feb 2021 | 55,038 | 436,713 (0%) | 0% | 7.2 | 395,723 | Common Stock |
| Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 5,362 | 0 | - | - | Restricted Stock Units | |
| Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 23,513 | 0 | - | - | Restricted Stock Units | |
| Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 79,380 | 79,380 | - | - | Restricted Stock Units | |
| Lonnel Coats | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 84,630 | 169,260 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 80,780 | 80,780 | - | - | Stock Option (Right to Buy) | |
| Alan J. Main | EVP, Innov & Chem Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 26,930 | 26,930 | - | - | Restricted Stock Units | |
| James F. Tessmer | VP, Finance & Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 24,340 | 24,340 | - | - | Stock Option (Right to Buy) | |
| James F. Tessmer | VP, Finance & Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 16,230 | 16,230 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 33,530 | 33,530 | - | - | Restricted Stock Units | |
| Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 100,600 | 100,600 | - | - | Stock Option (Right to Buy) | |
| Praveen Tyle | EVP, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 32,100 | 32,100 | - | - | Restricted Stock Units | |
| Praveen Tyle | EVP, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 96,310 | 96,310 | - | - | Stock Option (Right to Buy) | |
| Brian T. Crum | VP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 78,760 | 78,760 | - | - | Stock Option (Right to Buy) | |
| Brian T. Crum | VP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 26,250 | 26,250 | - | - | Restricted Stock Units | |
| Lonnel Coats | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Lonnel Coats | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 100,000 | 100,000 | - | - | Restricted Stock Units | |
| Frank P. Palantoni | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 16,368 (0%) | 0% | 0 | Common Stock | |
| Frank P. Palantoni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 18,115 | 18,115 | - | - | Stock Option (Right to Buy) | |
| Frank P. Palantoni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 10,638 | 10,638 | - | - | Restricted Stock Units | |
| Frank P. Palantoni | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 0 | - | - | Restricted Stock Units | |
| Raymond Debbane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 0 | - | - | Restricted Stock Units | |
| Raymond Debbane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 316,883 (0%) | 0% | 0 | Common Stock | |
| Raymond Debbane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 18,115 | 18,115 | - | - | Stock Option (Right to Buy) | |
| Raymond Debbane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 10,638 | 10,638 | - | - | Restricted Stock Units | |
| Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 18,115 | 18,115 | - | - | Stock Option (Right to Buy) | |
| Samuel L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 10,638 | 10,638 | - | - | Restricted Stock Units | |
| Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 0 | - | - | Restricted Stock Units | |
| Samuel L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 55,653 (0%) | 0% | 0 | Common Stock | |
| Alan S. Nies | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 10,638 | 10,638 | - | - | Restricted Stock Units | |
| Alan S. Nies | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 0 | - | - | Restricted Stock Units | |
| Alan S. Nies | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 18,115 | 18,115 | - | - | Stock Option (Right to Buy) | |
| Alan S. Nies | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 17,082 (0%) | 0% | 0 | Common Stock | |
| Christopher J. Sobecki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 140,759 (0%) | 0% | 0 | Common Stock | |
| Christopher J. Sobecki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 18,115 | 18,115 | - | - | Stock Option (Right to Buy) | |
| Christopher J. Sobecki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 10,638 | 10,638 | - | - | Restricted Stock Units | |
| Christopher J. Sobecki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 0 | - | - | Restricted Stock Units | |
| Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 18,115 | 18,115 | - | - | Stock Option (Right to Buy) | |
| Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 0 | - | - | Restricted Stock Units | |
| Philippe J. Amouyal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 10,638 | 10,638 | - | - | Restricted Stock Units | |
| Philippe J. Amouyal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 16,368 (0%) | 0% | 0 | Common Stock | |
| Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 16,368 (0%) | 0% | 0 | Common Stock | |
| Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 18,115 | 18,115 | - | - | Stock Option (Right to Buy) | |
| Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 10,638 | 10,638 | - | - | Restricted Stock Units | |
| Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 0 | - | - | Restricted Stock Units | |
| Robert J. Lefkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 10,638 | 10,638 | - | - | Restricted Stock Units | |
| Robert J. Lefkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 18,115 | 18,115 | - | - | Stock Option (Right to Buy) | |
| Robert J. Lefkowitz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 16,368 (0%) | 0% | 0 | Common Stock | |
| Robert J. Lefkowitz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2020 | 3,466 | 0 | - | - | Restricted Stock Units | |
| Alan J. Main | EVP, Commercial Supply Ops | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.96 per share. | 22 Apr 2020 | 6,813 | 104,640 (0%) | 0% | 2.0 | 13,353 | Common Stock |
| Alan J. Main | EVP, Commercial Supply Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Apr 2020 | 19,893 | 111,453 (0%) | 0% | 0 | Common Stock |